A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as flrst-line therapy for advanced colorectal cancer

被引:21
作者
Bouzid, K
Khalfallah, S
Tujakowski, J
Piko, B
Purkalne, G
Plate, S
Padrik, P
Serafy, M
Pshevloutsky, EM
Boussard, B
机构
[1] EHS Ctr Pierre & Marie Curie, Algiers 16005, Algeria
[2] Inst Salah Azaiz Bab Saadoun, Tunis, Tunisia
[3] Reg Centrum Oncol, Bydgoszcz, Poland
[4] Pandy K Bekescountry Cty Hosp, Gyula, Hungary
[5] Oncol Ctr Latvia, Riga, Latvia
[6] Clinicum Univ Tartu, EE-50090 Tartu, Estonia
[7] Natl Canc Inst, Cairo, Egypt
[8] Oncol Dispanser, Omsk, Russia
[9] Aventis Pharma, Global Med Affairs Oncol, Antony, France
关键词
colorectal cancer; first-line; 5-fluorouracil/folinic acid; irinotecan;
D O I
10.1093/annonc/mdg288
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer. Patients and methods: Patients were randomly assigned to receive intravenously either: CPT-11 125 mg/m(2), FA 20 mg/m(2) followed by 5-FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A, Saltz regimen); or CPT-11 180 mg/m(2) day 1 then FA 200 mg/m(2) over 2 h and 5-FU 400 mg/m(2) bolus and 5-FU 600 mg/m(2) 22-h infusion on days 1 and 2, every 2 weeks (arm B, Douillard regimen); or CPT-11350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5-FU bolus 425 mg/m(2)/day during 5 days (days 22-26) (arm C, Mayo Clinic regimen). Results: A total of 154 patients were included in the study (arm A, 51 patients; arm B, 53; arm C, 50). Overall response rates for the intention-to-treat populations were 33% [95% confidence interval (CI) 21% to 48%], 42% (95% CI 28% to 56%) and 30% (95% CI 18% to 45%) for arms A, B and C, respectively. Median times to progression were 6, 8 and 7 months for arms A, B and C, respectively. Median survival times were 15, 12 and 17 months for arms A, B and C, respectively. Overall response rates for the evaluable patient populations were 40% (95% CI 24% to 58%) in arm A, 44% (95% CI 29% to 60%) in arm B and 31% (95% CI 17% to 47%) in arm C. Neutropenia was the main serious adverse event in arms A (30% of patients) and C (22% of patients) but occurred in only 8% of patients in arm B. Delayed diarrhea was the main severe adverse event for the three regimens, from 15% to 22%. Conclusion: All three regimens were highly active. The biweekly combination of CPT-11 and 5-FU/FA (arm 13) was notable for its low incidence of grade 3/4 neutropenia. The incidence of grade 3/4 delayed diarrhea was equivalent for the three treatment arms.
引用
收藏
页码:1106 / 1114
页数:9
相关论文
共 21 条
[1]   Irinotecan is an active agent in untreated patients with metastatic colorectal cancer [J].
Conti, JA ;
Kemeny, NE ;
Saltz, LB ;
Huang, Y ;
Tong, WP ;
Chou, TC ;
Sun, M ;
Pulliam, S ;
Gonzalez, C .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :709-715
[2]   TOPOISOMERASE-I INHIBITORS - TOPOTECAN AND IRENOTECAN [J].
CREEMERS, GJ ;
LUND, B ;
VERWEIJ, J .
CANCER TREATMENT REVIEWS, 1994, 20 (01) :73-96
[3]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[4]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[5]   Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen):: A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer [J].
Ducreux, M ;
Ychou, M ;
Seitz, JF ;
Bonnay, M ;
Bexon, A ;
Armand, JP ;
Mahjoubi, M ;
Méry-Mignard, D ;
Rougier, P .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2901-2908
[6]  
Machover D, 1997, CANCER, V80, P1179, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1179::AID-CNCR1>3.0.CO
[7]  
2-G
[8]  
PIEDBOIS P, 1994, J CLIN ONCOL, V12, P960
[9]  
PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
[10]   Phase II trial of irinotecan in patients with metastatic colorectal carcinoma [J].
Pitot, HC ;
Wender, DB ;
OConnell, MJ ;
Schroeder, G ;
Goldberg, RM ;
Rubin, J ;
Mailliard, JA ;
Knost, JA ;
Ghosh, C ;
Kirschling, RJ ;
Levitt, R ;
Windschitl, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2910-2919